Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Immunological correlates of protection for the RTS,S candidate malaria vaccine.

Greenwood B.

Lancet Infect Dis. 2011 Feb;11(2):75-6. doi: 10.1016/S1473-3099(11)70001-9. Epub 2011 Jan 13. No abstract available.

PMID:
21237716
2.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.

Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P.

Lancet Infect Dis. 2011 Feb;11(2):102-9. doi: 10.1016/S1473-3099(10)70262-0. Epub 2011 Jan 13. Erratum in: Lancet Infect Dis. 2011 Mar;11(3):159.

3.

Efficacy of RTS,S malaria vaccine given with EPI vaccines.

Dicko A, Doumbo O.

Lancet Infect Dis. 2011 Oct;11(10):722-3. doi: 10.1016/S1473-3099(11)70186-4. Epub 2011 Jul 22. No abstract available.

PMID:
21782518
4.

Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.

Campo JJ, Sacarlal J, Aponte JJ, Aide P, Nhabomba AJ, Dobaño C, Alonso PL.

Vaccine. 2014 Apr 17;32(19):2209-16. doi: 10.1016/j.vaccine.2014.02.042. Epub 2014 Mar 11.

PMID:
24631081
5.

Humoral immune responses during a malaria vaccine trial in Tanzanian infants.

Galindo CM, Acosta CJ, Schellenberg D, Aponte JJ, Roca A, Oettli A, Urassa H, Armstrong Schellenberg J, Kahigwa E, Ascaso C, Mshinda H, Lwilla F, Vidal J, Menendez C, Tanner M, Alonso PL.

Parasite Immunol. 2000 Sep;22(9):437-43.

6.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitié MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M.

N Engl J Med. 2008 Dec 11;359(24):2533-44. doi: 10.1056/NEJMoa0807773. Epub 2008 Dec 8.

7.

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.

Olotu A, Clement F, Jongert E, Vekemans J, Njuguna P, Ndungu FM, Marsh K, Leroux-Roels G, Bejon P.

PLoS One. 2014 Dec 15;9(12):e115126. doi: 10.1371/journal.pone.0115126. eCollection 2014.

8.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitié MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L.

N Engl J Med. 2008 Dec 11;359(24):2521-32. doi: 10.1056/NEJMoa0807381. Epub 2008 Dec 8.

9.

Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.

Olotu AI, Fegan G, Bejon P.

J Infect Dis. 2010 Mar 15;201(6):970-1. doi: 10.1086/651025. No abstract available.

PMID:
20170369
10.

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL.

Vaccine. 2011 Aug 11;29(35):6059-67. doi: 10.1016/j.vaccine.2011.03.041. Epub 2011 Apr 7.

PMID:
21443960
11.

A malaria vaccine based on a sporozoite antigen.

Nussenzweig RS, Zavala F.

N Engl J Med. 1997 Jan 9;336(2):128-30. No abstract available.

PMID:
8988893
12.

Development of the RTS,S/AS malaria candidate vaccine.

Vekemans J, Leach A, Cohen J.

Vaccine. 2009 Dec 30;27 Suppl 6:G67-71. doi: 10.1016/j.vaccine.2009.10.013.

PMID:
20006143
13.

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J.

J Infect Dis. 1999 Nov;180(5):1656-64.

PMID:
10515829
14.

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ.

J Infect Dis. 2011 Jul 1;204(1):9-18. doi: 10.1093/infdis/jir222.

15.

Antibodies and Plasmodium falciparum merozoites.

Ramasamy R, Ramasamy M, Yasawardena S.

Trends Parasitol. 2001 Apr;17(4):194-7. Review.

PMID:
11282510
16.

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr; RTS,S Vaccine Evaluation Group.

J Infect Dis. 2009 Aug 1;200(3):337-46. doi: 10.1086/600120.

PMID:
19569965
17.

Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.

Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL.

Trop Med Int Health. 2007 Jan;12(1):37-46.

18.

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M.

N Engl J Med. 1997 Jan 9;336(2):86-91.

19.

Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine.

Schwenk R, Asher LV, Chalom I, Lanar D, Sun P, White K, Keil D, Kester KE, Stoute J, Heppner DG, Krzych U.

Parasite Immunol. 2003 Jan;25(1):17-25.

20.

Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.

Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR.

Am J Trop Med Hyg. 2006 Jul;75(1):166-70.

PMID:
16837726

Supplemental Content

Support Center